MedPath

FDA Revokes Emergency Use Authorization for Evusheld Due to Variant Ineffectiveness

• The FDA has revoked the emergency use authorization for Evusheld (tixagevimab/cilgavimab) in the U.S. due to its reduced efficacy against emerging SARS-CoV-2 variants. • Recent data indicates that Evusheld is unlikely to be effective against current dominant variants, such as XBB.1.5, which account for the majority of new infections. • The decision was based on updated CDC projections showing the prevalence of variants against which Evusheld offers limited protection. • Alternative COVID-19 treatment options are expected to remain effective against the currently circulating SARS-CoV-2 variants.

The Food and Drug Administration (FDA) has announced the revocation of the emergency use authorization (EUA) for Evusheld (tixagevimab/cilgavimab) in the United States, effective January 26. This decision follows data indicating that Evusheld is unlikely to be active against several recent SARS-CoV-2 variants, including the XBB.1.5 variant.
According to the FDA, the increasing prevalence of variants against which Evusheld offers limited protection prompted the revocation. New data from the Centers for Disease Control and Prevention (CDC) projects that XBB.1.5 and related SARS-CoV-2 variants are responsible for the majority of current infections. This renders Evusheld unlikely to protect patients against the most common circulating variants.
Evusheld, a combination of two monoclonal antibodies, had been authorized for emergency use in certain populations at high risk for severe COVID-19. However, the emergence and rapid spread of new variants have challenged the efficacy of several monoclonal antibody treatments.
While Evusheld is no longer authorized, other treatment options for COVID-19 are expected to remain effective against the currently circulating variants. Healthcare providers are advised to consider these alternative treatments when managing COVID-19 in their patients.
Subscribe Icon

Stay Updated with Our Daily Newsletter

Get the latest pharmaceutical insights, research highlights, and industry updates delivered to your inbox every day.

Related Topics

FDA Revokes Emergency Use Authorization for Bebtelovimab Due to Expired Lots and Variant Resistance

The FDA revoked the Emergency Use Authorization (EUA) for bebtelovimab on December 5, 2024, following a request from Lilly due to the expiration of all manufactured lots.
Bebtelovimab was no longer authorized for use in regions where SARS-CoV-2 variants demonstrated resistance, based on available susceptibility data and variant frequency.

FDA Revokes Emergency Use Authorization for Sotrovimab

The FDA has revoked the Emergency Use Authorization (EUA) for sotrovimab due to the expiration of all manufactured lots under EUA 100.
GSK requested the EUA revocation on November 22, 2024, as sotrovimab was not authorized for use against non-susceptible SARS-CoV-2 variants.

FDA Revokes Emergency Use Authorizations for COVID-19 Antibody Treatments Evusheld and REGEN-COV

The FDA has revoked the Emergency Use Authorization (EUA) for AstraZeneca's Evusheld due to the expiration of all distributed lots and high prevalence of non-susceptible variants.
Regeneron requested the FDA revoke the EUA for REGEN-COV because all manufactured lots have expired, and the company no longer intends to offer the product in the United States.

FDA Revokes Emergency Use Authorizations for Four COVID-19 Monoclonal Antibody Products

The FDA has revoked the Emergency Use Authorizations (EUAs) for four monoclonal antibody products used in the U.S. government's COVID-19 response.
The revoked EUAs include treatments from Eli Lilly, AstraZeneca, Vir Biotechnology, and Regeneron Pharmaceuticals due to the rise of resistant SARS-CoV-2 variants.

FDA Revokes Emergency Use Authorizations for Four Monoclonal Antibody Treatments Due to Variant Resistance

The FDA has revoked the Emergency Use Authorizations (EUAs) for four monoclonal antibody (mAb) products previously used to treat COVID-19 due to persistent resistance from circulating SARS-CoV-2 variants.
These mAbs have not been authorized for patient administration for over a year because of the high prevalence of SARS-CoV-2 variants against which they are ineffective.

FDA Warns Evusheld May Be Ineffective Against COVID-19 Subvariant XBB.1.5

The FDA has cautioned that Evusheld, a preexposure prophylaxis for COVID-19, may not neutralize the XBB.1.5 subvariant, which accounts for nearly 30% of cases.
The agency is awaiting further data but suggests that Evusheld's effectiveness is compromised against XBB.1.5 compared to other variants.

FDA Restricts Emergency Use Authorization for AstraZeneca's Evusheld in the US

The FDA has restricted the emergency use authorization for AstraZeneca's Evusheld in the US due to the prevalence of resistant SARS-CoV-2 variants.
Evusheld is not currently authorized for pre-exposure prophylaxis of COVID-19 in the US until the prevalence of resistant variants decreases.

FDA Revokes Emergency Use Authorization for Bebtelovimab

The FDA revoked the Emergency Use Authorization (EUA) for bebtelovimab 175mg on November 30, 2022, due to its diminished efficacy against emerging COVID-19 variants.
Bebtelovimab, a monoclonal antibody infusion treatment developed by Eli Lilly, was previously authorized for treating mild-to-moderate COVID-19 in certain high-risk patients.

FDA Restricts Sotrovimab Use Due to Omicron BA.2 Variant Resistance

The FDA has suspended the authorization of GlaxoSmithKline and Vir Biotechnology's sotrovimab in regions where the Omicron BA.2 subvariant is dominant, citing inefficacy.
Sotrovimab, a monoclonal antibody, was previously authorized for treating high-risk COVID-19 patients but shows reduced effectiveness against the BA.2 subvariant.

FDA Revokes Emergency Use Authorization for Bamlanivimab Monotherapy Against COVID-19

The FDA revoked the EUA for bamlanivimab monotherapy due to increasing SARS-CoV-2 variants resistant to the treatment, raising the risk of treatment failure.
Data from the CDC showed a significant increase in resistant variants, from 5% in mid-January to approximately 20% in mid-March 2021.

Reference News

[1]
FDA Revokes Emergency Use Authorization for Evusheld
the-rheumatologist.org · Sep 28, 2023

FDA revoked authorization for Evusheld due to its ineffectiveness against recent SARS-CoV-2 variants like XBB.1.5, now r...

© Copyright 2025. All Rights Reserved by MedPath
HomeTerms & ConditionsPrivacy Policy